Maizel Ari
Chief Commercial Officer
Maizel Ari has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Apr 23, 2026.
On the most recent filing, Maizel Ari is listed as Chief Commercial Officer at Axsome Therapeutics, Inc. Inside the rolling window, Maizel Ari reported no open-market purchases and 2 open-market sales totaling $2.8M in AXSM. The largest disclosed transaction in the window is a sale of 7,500 AXSM shares on Jan 21, 2026, worth $1.4M.
Companies traded
Other insiders at AXSM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.8M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Maizel Ari made?
Maizel Ari has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Maizel Ari trade?
Maizel Ari has filed SEC Form 4 disclosures for 1 company, including AXSM.
When was Maizel Ari's most recent SEC Form 4 filing?
Maizel Ari's most recent SEC Form 4 filing on Tracefour is dated Apr 23, 2026.
What is Maizel Ari's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Maizel Ari is listed as Chief Commercial Officer.
What is Maizel Ari's total buy and sell value in the current window?
Inside the rolling retention window, Maizel Ari bought $0 and sold $2.8M based on SEC Form 4 filings.
What was Maizel Ari's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,500 AXSM shares on 2026-01-21, worth $1.4M, per SEC Form 4 filings.